Immunoaffinity chromatography occupies a special place in modern bioprocessing. By exploiting the exquisite specificity of antibodies for their antigens, it allows a desired protein to be pulled out of a complex mixture based on epitopes displayed on its surface, a capability that applies to nearly every antigen imaginable. Yet the technique is expensive and technically demanding at industrial scale, and its success hinges on the properties of the immobilized ligand. Conventional immunoglobulins are large, fragile molecules that can denature under the harsh acidic or alkaline conditions used to strip bound product from a column, shortening resin lifespan and raising costs. The variable domain of camelid heavy-chain antibodies, known as VHH or nanobody, has emerged as a compelling alternative. These roughly 15-kilodalton fragments are small, remarkably stable, and resistant to conditions that destroy ordinary antibodies, and they have already proven their worth commercially in resins such as the CaptureSelect family used across the biopharmaceutical industry.

Recombinant factor VII presents a particularly demanding purification challenge. The protein is expressed in baby hamster kidney cells and is both thermally sensitive and structurally fragile, requiring a rapid series of downstream steps to preserve its integrity. Because the drug is administered in its active form, activation at the end of the bioprocess is essential. At least one affinity chromatography step is indispensable, and the newest commercial solution, VIISelect from GE Healthcare, relies on a camelid VHH ligand discovered from an immune llama antibody library. Immune libraries, however, require animal immunization, a drawback that limits their use against toxic, poorly immunogenic, or otherwise unsuitable antigens. Synthetic libraries sidestep this limitation entirely, allowing binders to be discovered against an essentially unrestricted range of targets through rational design of molecular diversity.

The research team, led by Aliasghar Rahimian, Ali Nabati, Hooman Askari, and Mahdi Aminian, drew on two anti-factor VII nanobodies, designated VHH19 and VHH24, which they had previously isolated from a phage-displayed synthetic VHH library built on the cAbBCII-10 scaffold. This framework is prized for its exceptional stability, its plasticity for grafting diverse antigen-binding loops, and its acceptable expression yield in bacteria. The two binders carried affinity constants of 10 to the power of minus eight and 5.8 times 10 to the power of minus eight, respectively, indicating tight binding to the coagulation factor. The team expressed the nanobodies in the periplasm of TG1 bacterial cells on a five-liter scale, recovered them through osmotic shock, and purified them sequentially on nickel-affinity resin and Sephacryl S-100 gel filtration to remove aggregates and polymers. Yields reached approximately 0.8 milligrams per liter for VHH19 and 1 milligram per liter for VHH24, with reducing SDS-PAGE revealing the expected doublet of native and disulfide-reduced forms around 15 kilodaltons.

Before committing the binders to a column format, the researchers verified their specificity by enzyme-linked immunosorbent assay. Both purified VHHs produced strong, concentration-dependent signals on wells coated with recombinant factor VII, while signals on wells coated with diluted human blood plasma, used as a source of non-specific antigens, remained at baseline across all coating concentrations. This clean discrimination against the thousands of proteins present in plasma is a critical prerequisite for any ligand intended to purify a therapeutic protein from biological feedstocks. Encouraged by these results, the team coupled each nanobody to cyanogen bromide-activated cross-linked agarose beads, a classical chemistry that converts agarose hydroxyl groups into cyanate esters reactive with protein amino groups. By measuring protein remaining in the coupling supernatant, they determined that coupling efficiency exceeded 95 percent for both binders, yielding resins containing approximately 2 milligrams of immobilized VHH per milliliter of gel.

The decisive test came in column chromatography, where the chemistry of calcium binding to the Gla domain of factor VII shaped the optimization strategy. Calcium association is essential to the conformation and enzymatic activity of the protein, so the team screened four buffering systems that varied the presence of calcium chloride and EDTA during binding and elution. The outcome was unambiguous: only the VHH19-based resin, designated Seph4B-VHH19, captured factor VII effectively, and only when calcium chloride was present in the binding and washing buffers. Under those conditions the factor VII concentration in the flow-through was depleted almost completely, whereas procedures lacking calcium produced partial or negligible adsorption. EDTA proved unable to elute the bound protein, leaving acidic glycine-hydrochloric acid buffer at pH 2.2 as the effective desorption agent. The VHH24 column and an uncoupled control resin retained the protein poorly or not at all under every condition tested, and both were excluded from further study.

With the optimal conditions established, the researchers benchmarked their resin against the commercial VIISelect medium using breakthrough curve analysis on a partially purified, inactive factor VII feed. Seph4B-VHH19 processed 28 plus or minus 1 milliliter of feed before breakthrough, yielding 2.3 plus or minus 0.15 milligrams of eluted protein per milliliter of resin, compared with 42 plus or minus 1 milliliter and 4.08 plus or minus 0.06 milligrams per milliliter for VIISelect. The authors attribute roughly half of this capacity gap to ligand density: the commercial resin reportedly carries about 6 milligrams of ligand per milliliter, double the loading achieved with their research-scale periplasmic expression system. They argue the comparison should be read as a feasibility demonstration rather than a head-to-head performance contest, noting that industrial expression improvements and more sophisticated coupling chemistries could readily narrow the difference.

Two further results stand out for bioprocess engineers. First, the resin proved operationally robust: it performed consistently across four consecutive chromatography cycles, and although cleaning with 0.1 molar sodium hydroxide before a fifth cycle cost 15 percent of the dynamic binding capacity, the column retained that reduced capacity after a full month of storage at 4 degrees Celsius. The limited alkaline tolerance marks a clear target for future sequence optimization and cleaning-procedure refinement. Second, and perhaps more striking, the column accomplished on-column activation of the drug substance. When a mixture of partially purified inactive factor VII and human plasma was passed through Seph4B-VHH19, the resin excluded a substantial portion of the plasma contaminants, and the eluted factor VII appeared as two chains of 20 to 30 kilodaltons on reducing SDS-PAGE, the signature of autocleavage. Activity assays confirmed the transformation: eluate fractions reached 26.8 kilo-international units per milliliter, roughly two hundred times the 0.12 KIU per milliliter measured in the pre-column sample, while flow-through and wash fractions carried almost none of the activity.

This activation step matters because commercial factor VII production is not complete without it; in existing downstream processes, activation occurs as a byproduct of concentration during ion-exchange chromatography. The nanobody column reproduced that behavior naturally, concentrating the protein enough to trigger autocleavage as it bound. The authors place their work in a broader context of nanobody-based affinity media, which have already been engineered for demanding targets such as adeno-associated virus serotype 8 and for separating closely related product forms of low-abundance plasma proteins. Nanobodies resist aggregation because they lack the variable light-chain domain, their frameworks can be fully humanized, and the cAbBCII-10 scaffold offers exceptional plasticity for CDR grafting. The synthetic library approach eliminates animal immunization and permits rational targeting of difficult antigens, though the absence of in vivo affinity maturation means isolated clones may need additional in vitro optimization to match the affinity profiles of immune-derived counterparts.

The study also exposes a knowledge gap that the authors hope the field will fill. Few publications assess how different conjugation methods and linkers affect the performance of VHH affinity columns, and the cyanogen bromide chemistry used here, while simple and traditional, immobilizes ligands in random orientations. Site-specific immobilization strategies, including engineered tag systems, have been shown to improve both capacity and resin stability compared with random amine coupling, and the team has published the sequence of VHH19 to encourage such exploration. For an industry that already generates billions of dollars in value from VHH-based CaptureSelect resins, the demonstration that a fully synthetic, animal-free discovery pipeline can produce a functional purification ligand for a fragile, medically critical coagulation protein signals a practical new route to affinity media, one that could extend to toxic, poorly immunogenic, or otherwise inaccessible targets where immunized llamas simply cannot help.

Subject of Research: Synthetic camelid nanobody binders for immunoaffinity purification of recombinant coagulation factor VII

Article Title: Application of camelid nanobody binders derived from a novel full-synthetic VHH library in immunoaffinity purification of recombinant coagulation factor VII

Article References: Rahimian, A., Nabati, A., Askari, H., & Aminian, M. (2026). Application of camelid nanobody binders derived from a novel full-synthetic VHH library in immunoaffinity purification of recombinant coagulation factor VII. Heliyon, 12(15), Article e45524. https://doi.org/10.1016/j.heliyon.2026.e45524

Image Credits: AI Generated

DOI: Not provided

Keywords: nanobodies, VHH, synthetic antibody library, coagulation factor VII, immunoaffinity chromatography, bioprocessing, hemophilia, affinity resin, phage display, recombinant protein purification, cyanogen bromide coupling, downstream processing

Researchers at University College London, working with scientists at AstraZeneca, report the successful miniaturisation of a semi-perfusion cell screening method from a 24-well microwell plate format down to a 96-well deepwell plate, and then combined it with a multi-parameter ranking tool known as the manufacturability index. The work, led by Marie Dorn with colleagues Christine Ferng, Kerensa Klottrup-Rees, Kenneth Lee and Martina Micheletti, addresses a growing tension in bioprocessing: while manufacturing has been steadily shifting from traditional fed-batch culture toward continuous perfusion, clone screening has remained stubbornly fed-batch, conducted at microlitre or millilitre scale long before perfusion conditions are ever introduced at the bench.

The rationale for closing this gap is grounded in physiology. In fed-batch culture, cells are fed once or a few times and accumulate waste products as nutrients are depleted, so the environment changes dramatically over the run. Perfusion culture, by contrast, continuously exchanges medium while retaining cells, keeping conditions far more stable and allowing much higher cell densities. Because the culture environment shapes cell growth and productivity, clones that look mediocre in fed-batch screening might excel under perfusion—and vice versa. Previous studies have shown that screening under production-representative conditions can alter clone rankings, meaning that conventional fed-batch screens risk discarding clones that would have been the best performers in the actual manufacturing process.

The team had previously validated a semi-perfusion screening method at the 24-well microwell plate scale, demonstrating that operation mode and perfusion rate significantly influence clone performance. But industrial screening pipelines overwhelmingly rely on the smaller 96-well deepwell plate format, which is supported by mature automation hardware, software and user expertise. Adapting semi-perfusion to that format was therefore the logical next step to make production-representative screening compatible with the high-throughput automated workflows that pharmaceutical companies already run. The challenge was that miniaturisation introduces new physical constraints: the team’s shaker platform was limited to a maximum agitation speed of 300 rpm with a 19-millimetre orbital diameter, below the 320 to 350 rpm and larger diameters typically reported for deepwell plate work.

To find workable conditions, the researchers first ran preliminary experiments with a CHO Cobra cell line, testing working volumes between 200 and 400 microlitres. Growth proved feasible at 200 and 300 microlitres, while higher volumes impaired culture performance—likely due to insufficient mixing and oxygen transfer at the limited agitation speed. Encouragingly, cell performance at the validated volumes was comparable to previously published 24-well plate data, giving the team confidence the smaller system could deliver trustworthy results. The final screening protocol used squared 96-well deepwell plates sealed with Duetz sandwich lids to minimise evaporation while preserving gas exchange, with a daily partial medium exchange of 0.75 reactor volumes per day mimicking perfusion with cell retention over a ten-day culture period.

With the platform established, the team screened eight clonally derived Chinese hamster ovary cell lines, all producing the same proprietary monoclonal antibody, at both 200 and 300 microlitre working volumes. Growth dynamics were highly comparable between the two volumes, though a trend toward better sustained growth emerged at 200 microlitres, with cultures at 300 microlitres showing earlier declines in viable cell concentration and viability—consistent with possible inhibitory effects or oxygen limitation at the higher volume. Maximum viable cell concentrations ranged widely, from roughly 5 to 35 million cells per millilitre, revealing substantial natural variation among clones. Space-time yield, a measure of how much product a given culture volume produces per day, peaked between 0.04 and 0.14 grams per litre per day, with a couple of clone-specific anomalies that the authors attribute to analytical variability in HPLC-based protein quantification at very low concentrations.

The heart of the study lies in how the clones were ranked. Traditional selection relies on a single metric—typically cell-specific productivity, the amount of antibody each cell produces per day. When the team ranked the eight clones by this single parameter, the results were sobering. Within the 96-well plate system, rankings were internally consistent across the two working volumes, with clone mAb1_C5 topping both lists and mAb1_C7 consistently last. But when those rankings were compared against the earlier 24-well plate data, only the very best and very worst clones held their positions. Mid-ranked clones shuffled dramatically: mAb1_C4 placed second in both 24-well runs but only fourth or fifth in the deepwell plates, while mAb1_C6 performed far better in the smaller format. In short, single-parameter rankings were robust within a platform but did not travel across scales.

Enter the manufacturability index. Originally developed by Goldrick and colleagues, this metric treats clone selection as a multi-criteria decision-making problem, folding growth, viability, productivity and other indicators into a single composite score in which each parameter is rated against the best and worst performer and weighted according to process priorities. Because the 96-well format’s tiny working volumes limited sampling, the index here used five parameters—maximum viable cell concentration, minimum viability, growth rate, space-time yield and average cell-specific productivity—compared with ten parameters, including five metabolite-related metrics, in the larger 24-well system. Even with the reduced parameter set, the multi-parameter rankings proved markedly more consistent. The same three clones occupied the top three positions at both working volumes, and cross-scale agreement with the 24-well data was stronger than for the single-parameter approach.

Statistical analysis reinforced the story. Spearman rank correlations showed that manufacturability index rankings at 200 microlitres agreed significantly with both 24-well plate runs, with correlation coefficients of 0.714 and 0.690, the latter just missing the conventional significance threshold. Single-parameter rankings, by contrast, reached significance against one 24-well run but not the other, exposing their vulnerability to run-to-run variability. The authors are appropriately cautious: with only eight clones, far fewer than the hundred-plus typical of industrial campaigns, the correlations indicate trends rather than definitive proof. Still, the internal coherence of the results, combined with the clear mechanistic advantage of evaluating clones on multiple fronts, lends weight to the conclusion that richer metrics make early screening more predictive.

The implications reach well beyond one plate format. As biopharmaceutical manufacturing continues its march toward intensified and continuous processes, the ability to screen clones under conditions that genuinely represent production—early, cheaply and at high throughput—becomes a strategic advantage, shortening development timelines and preventing costly late-stage surprises. The authors point toward integrating product quality attributes into the index and harnessing machine learning, multivariate data analysis and automation to push predictive power further. For an industry whose approvals have increased three- to four-fold since 2015, and in which monoclonal antibodies remain the leading class of new therapeutics, choosing the right cell clone on day one may prove one of the highest-leverage decisions in the entire manufacturing chain. This study suggests the industry now has a scalable, data-rich way to make that choice well.

Subject of Research: Miniaturised semi-perfusion screening and multi-parameter manufacturability ranking of CHO cell clones for perfusion biomanufacturing

Article Title: Improved clone selection by combining a manufacturability index with semi-perfusion scale-down screening systems

Article References: Dorn, M., Ferng, C., Klottrup-Rees, K., Lee, K., & Micheletti, M. (2026). Improved clone selection by combining a manufacturability index with semi-perfusion scale-down screening systems. Current Research in Biotechnology, Article 100423. https://doi.org/10.1016/j.crbiot.2026.100423

Image Credits: AI Generated

DOI: 10.1016/j.crbiot.2026.100423

Keywords: CHO cells, clone selection, semi-perfusion, perfusion bioprocessing, manufacturability index, deepwell plates, monoclonal antibodies, cell line development, scale-down models, space-time yield, bioprocess intensification, high-throughput screening

The review, authored by Yuefan Zhang, Yan Zhang, Shuo Xia, Aamer Ali Shah, Rui Zhang and corresponding author Chunjie Gong of Hubei University of Technology and collaborating institutions, arrives at a moment when demand for xylitol is climbing alongside the global rise in diabetes. Unlike sucrose, xylitol delivers sweetness with a low glycemic impact, and decades of research have linked it to benefits ranging from cavity prevention to possible roles in respiratory health, skin barrier function and gut microbiome modulation. But producing it at industrial scale remains expensive, and the new analysis argues that the answer lies not in better chemistry but in smarter biology.

At the heart of the biological route is a single enzymatic step. Xylose, a five-carbon sugar abundant in hemicellulose from agricultural waste such as corncobs, sugarcane bagasse, wheat straw and rice straw, is reduced to xylitol by the enzyme xylose reductase. In nature, yeasts such as Candida tropicalis, Candida guilliermondii, Debaryomyces hansenii and Yarrowia lipolytica perform this conversion, and bacteria including Enterobacter species and engineered Escherichia coli can be coaxed to do the same. The catch is that the reaction consumes reduced nicotinamide cofactors, NADH or NADPH, which the cell must continuously regenerate. When cofactor supply runs dry, production stalls, and unwanted byproducts accumulate as the microbe reroutes carbon elsewhere.

This cofactor bottleneck is precisely where modern metabolic engineering has made its mark. The review details how researchers have rebuilt xylitol pathways from the ground up: overexpressing xylose reductase, deleting xylitol dehydrogenase so the product cannot be consumed again, and rewiring the pentose phosphate pathway to pump out the NADPH the reductase demands. In engineered E. coli, teams have multiplied copies of the xylose reductase gene while deleting genes of the Embden-Meyerhof-Parnas glycolytic route, forcing carbon flux toward NADPH regeneration and sharply improving yields. Similar logic has been applied in yeasts, where co-expression of pentose phosphate pathway genes in Candida tropicalis boosted xylitol titers, and disruption of the xylitol dehydrogenase gene under fully aerobic conditions raised both productivity and yield.

Beyond single-gene interventions, the field has embraced modular design. Rather than tweaking one enzyme at a time, synthetic biologists now assemble pathway modules that can be independently tuned, balancing expression strengths through choices of promoters and ribosome binding sites. Dynamic control systems add another layer of sophistication: in engineered E. coli, researchers have placed feedback regulatory loops under programmable control, improving NADPH flux and xylitol biosynthesis simultaneously. Cofactor engineering has even extended to redesigning the coenzyme specificity of central metabolic enzymes, a strategy proven in other products and increasingly relevant to xylitol, where the balance between NADH and NADPH dictates how much reducing power is available for the key reductive step.

Choice of host organism matters as much as pathway design. The review weighs the trade-offs among industrial chassis cells: natural xylose-fermenting yeasts like Candida and Debaryomyces species are robust on lignocellulosic hydrolysates but may not be food-grade; the baker’s yeast Saccharomyces cerevisiae is Generally Recognized As Safe and genetically tractable but needs extensive engineering to consume xylose efficiently; E. coli grows fast and tolerates manipulation but raises regulatory hurdles for food applications. Thermotolerant hosts such as Kluyveromyces marxianus offer the bonus of high-temperature fermentation, cutting cooling costs, while oleaginous yeasts like Yarrowia lipolytica can co-consume crude glycerol and xylose, turning two waste streams into one product. Even filamentous fungi have entered the arena, with engineered Neurospora crassa producing xylitol from xylose and Aspergillus niger converting L-arabinose into the sweetener.

Feedstock strategy is evolving in parallel. Hemicellulosic hydrolysates from corncob, sugarcane bagasse, wheat straw, rapeseed straw and even banana peel provide cheap xylose, but they carry inhibitors, furans and acids, that poison fermentation, requiring detoxification steps. Recent work has explored co-substrate models that pair xylose with other sugars to sustain cofactor regeneration, and a striking new mode uses the microalga Chlorella sorokiniana driven synergistically by light and co-substrates to biosynthesize xylitol, hinting at photosynthesis-assisted production. Adaptive laboratory evolution, in which strains are bred for tolerance to hydrolysate toxins over many generations, rounds out the toolkit for making industrial feedstocks usable.

The most forward-looking section of the review concerns artificial intelligence. Machine learning models, from artificial neural networks and support vector regression to deep neural networks, are already predicting fermentation outcomes and optimizing bioreactor parameters, with early demonstrations coupling neural networks to genetic algorithms to maximize xylitol production by Debaryomyces nepalensis. Protein language models and structure-prediction systems of the AlphaFold era now allow researchers to forecast enzyme properties and steer directed evolution of xylose reductases toward higher activity and better cofactor preference, while deep learning tools navigate biosynthetic pathways for natural products. Genome-scale metabolic models fused with machine learning can characterize cell growth from multi-omics data, and multimodal networks promise to integrate fermentation time-courses with transcriptomic and flux information into unified predictive frameworks.

All of this feeds into what the authors describe as a closed-loop design-build-test-learn cycle. In this framework, AI predicts metabolic network behavior and proposes enzyme variants; automated construction builds the strains; high-throughput testing measures performance; and the results are fed back to refine the models. Computational fluid dynamics and process modeling extend the loop from the cell to the bioreactor, while techno-economic and sustainability analyses, including assessments of xylitol production within integrated biorefinery platforms aimed at circular economies, evaluate whether bio-xylitol can compete with petrochemical and catalytic hydrogenation routes on cost and carbon footprint.

The review is candid about remaining obstacles: enzymatic bottlenecks, carbon flux imbalances, feedstock variability, downstream purification costs and the regulatory demands of food-grade production all persist. It also notes that the health conversation around xylitol is not settled, with recent research reporting potential prothrombotic associations that warrant attention even as dental and metabolic benefits remain well documented. Still, the authors conclude that the convergence of rational metabolic engineering, food-grade chassis optimization and AI-guided bioprocessing provides a comprehensive blueprint for making microbial xylitol economically viable. If the design-build-test-learn loop matures as its proponents hope, the sweetener in sugar-free gum and diabetic-friendly foods may soon come from fermentation tanks where algorithms, not just chemists, decide what the microbes make next.

Subject of Research: Metabolic engineering and AI-driven bioprocessing of microbial cell factories for xylitol production

Article Title: Advances in microbial cell factories for substitute sugar xylitol production: from metabolic engineering to AI-driven bioprocessing

Article References: Zhang, Y., Zhang, Y., Xia, S., Shah, A. A., Zhang, R., & Gong, C. (2026). Advances in microbial cell factories for substitute sugar xylitol production: from metabolic engineering to AI-driven bioprocessing. 3 Biotech, 16(10), Article 427. https://doi.org/10.1007/s13205-026-05072-8

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05072-8

Keywords: xylitol, metabolic engineering, microbial cell factories, xylose reductase, cofactor engineering, synthetic biology, artificial intelligence, bioprocessing, lignocellulosic biomass, sugar substitute, pentose phosphate pathway, industrial biotechnology

The significance of the harvest step is easy to underestimate. In a typical manufacturing train, human embryonic kidney 293 (HEK293) cells are cultivated in bioreactors and transfected to produce viral vectors, after which a chemical lysis step releases the particles from the cells. What remains is a murky soup of viral vectors, host cell proteins, host cell DNA, and fragmented cellular material. Before chromatography-based purification can begin, this crude lysate must be clarified, and the efficiency of that clarification determines how much product survives and how smoothly downstream operations run. At laboratory scales of up to roughly 10 liters, centrifugation handles the job well, but single-use centrifuge technologies cannot deliver the required centrifugal forces at production scale, forcing manufacturers to rely on filtration instead.

Depth filtration has long been the industry standard for this task. These filters contain a porous multilayer matrix of fibrous material and filter aids such as diatomaceous earth, and they are valued for their high retention capacity and their ability to remove not only cell debris but also meaningful quantities of host cell proteins and DNA. However, the Roche team identified a critical weakness when they systematically screened ten depth filters or filter combinations using lysate from rAAV8-producing cultures in 1 to 3 liter test volumes. Capacity values ranged widely, from 20 to 300 liters per square meter of filter area, with turbidity reductions generally exceeding 90 percent for the better performers. The synthetic Millistak+ HC Pro D0SP filter emerged as the clear favorite, achieving approximately 300 liters per square meter, followed by Clarisolve 20MS at roughly 240 and Millistak+ HC Pro C0SP at 120 liters per square meter.

The problem lay not in performance but in geometry. The largest filter area available per fully closed single-use capsule of the best-performing depth filter was limited to 0.027 square meters. Scaling calculations for a 500 liter harvest revealed that closed processing would require roughly 50 such lab-scale capsules, an impractical proposition, while the cassette-based alternative that provides adequate area requires a multi-use filter holder whose disassembly cannot be performed under closed conditions. This matters because rAAV vector variants classified as risk group 2 fall under German biosafety regulations that prescribe a fully closed system whenever no separate space exists for the disassembly and cleaning of equipment outside the production area. A fully closed system, as defined in the study, fully isolates cells and viral vectors from the environment throughout processing.

Alluvial filtration, also known as body feed filtration, offered a way around this constraint. Rather than relying on a fixed filter matrix alone, the technique adds diatomaceous earth directly to the feed, where it forms a porous, incompressible cake on the filter sheet that acts as the working filtration medium. This cake resists blockage, supports high flow rates of around 300 liters per square meter per hour or more, and enables efficient impurity removal. The Roche team, building on earlier small-scale work conducted at merely 50 milliliters by other groups, optimized the method across combinations of filter sheets, diatomaceous earth grades, and dosing ratios. The winning configuration paired the PURAFIX CH 31 filter sheet with Celpure C 300 diatomaceous earth at a ratio of 2 grams of filter aid per 3 grams of biological wet mass, the latter determined gravimetrically from centrifuged samples of each feed.

In head-to-head small-scale comparisons using 1 to 3 liter feeds, the optimized alluvial method matched the best depth filter in capacity at approximately 300 liters per square meter while surpassing it on nearly every other measure. Alluvial filtration achieved complete removal of host cell DNA, a 75 percent reduction in host cell protein, 97 percent turbidity reduction, and product recoveries of 95 percent for viral genomes and 97 percent for capsids. The absolute turbidity after filtration was slightly higher than with the leading depth filter, 63 versus 40 nephelometric turbidity units, but remained comfortably within the range suitable for subsequent sterile filtration. The method also operated at a recommended flux of 480 liters per square meter per hour, more than three times the depth filter recommendation, translating into substantially shorter processing times.

The real test came at scale. The researchers processed lysate from bioreactors at 10, 100, and 500 liters, spanning process development, initial supplies, and pilot-scale study material. The runs covered three rAAV variants, rAAV2, rAAV8, and rAAV9, providing a stress test of robustness across different vector serotypes and feedstock compositions. Average filter capacities came in at 223, 256, and 229 liters per square meter for the three scales respectively, a remarkably consistent band. Product recovery and turbidity reduction stayed high at every scale with no decline at 500 liters, and standard deviations remained acceptable. Impurity reduction for host cell DNA and protein showed larger variability, a deliberate trade-off in favor of capacity, which the authors judged acceptable since robust lysate processing, not maximal impurity clearance, is the critical objective at this initial stage.

Pressure profiles from a representative 500 liter run told a story of a process operating well within its limits. Pressure before the alluvial filter rose to 1.15 bar at the start of filtration and then held nearly constant, while downstream pressure stabilized at 0.75 bar and flow declined only marginally from 12 to 10 liters per minute, a drop attributed to the centrifugal pump rather than filter clogging. The entire 405 liter filtration finished in approximately 30 minutes, matching the calculated projection, and pressure never approached the 1.5 bar safety limit. The filter cake volume also stayed below the module maximum, indicating that the system’s full capacity was never reached and that the process could tolerate even higher-turbidity feedstocks. A sterile filtration stage downstream of the alluvial filter performed without blocking or product loss, confirming the filtrate was fit for purification.

Safety engineering rounded out the design. Because filtration trains are generally classified as high-risk unit operations prone to equipment failure and pressure buildup, the pilot-scale setup incorporated single-use pumps, sterile couplings, and pressure-rated tubing, along with continuous monitoring by pressure and flow sensors. If system pressure reached the 1.5 bar maximum, flow was automatically reduced to prevent exceedance. Before any viral vector-containing fluid entered the train, all connections were checked, filters were vented during a water pre-rinse, and the housing and connections were validated by a water pressure test. Disassembly was performed by tube welding and sealing, allowing the used filter to be removed and autoclaved for viral inactivation without ever opening the system.

The study’s authors conclude that alluvial filtration meets both the performance and biosafety requirements that the best available depth filter could not satisfy at pilot scale, offering up to 2.71 square meters of filter area in a single closed module where the leading depth filter capsule provides only 0.027 square meters. The method does demand roughly an hour of additional preparation to measure biological wet mass and suspend the filter aid, but this is more than compensated by filtration times cut more than threefold. As demand for rAAV-based gene therapies continues to climb, the ability to harvest viral vectors safely, quickly, and at the 500 liter scale within a fully closed single-use train may prove a meaningful step toward industrial-scale production of these transformative medicines.

Subject of Research: Alluvial filtration for scalable, closed-system harvest clarification of recombinant adeno-associated viral vectors in gene therapy manufacturing

Article Title: Alluvial filtration as a scalable and safe single-use technology for the harvest of viral vectors

Article References: Wiesner, J., Bauer, A., & Eisenkraetzer, D. (2026). Alluvial filtration as a scalable and safe single-use technology for the harvest of viral vectors. Applied Microbiology and Biotechnology, 110(1), Article 293. https://doi.org/10.1007/s00253-026-14035-1

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14035-1

Keywords: alluvial filtration, rAAV vectors, gene therapy, viral vector manufacturing, depth filtration, diatomaceous earth, harvest clarification, single-use technology, bioprocessing, HEK293 cells, pilot-scale production, biosafety

The study, published in Applied Microbiology and Biotechnology, set out to answer a question that has been asked repeatedly in the cultured meat community but seldom resolved with such systematic rigor: can sera from adult cattle, pigs, and chickens, collected as a byproduct of ordinary meat processing, support the demanding growth requirements of muscle cells destined for cultured meat? The answer, according to the research led by Da-Young Lee and corresponding author Sun Jin Hur, is a qualified but emphatic yes, provided the sera are carefully characterized and supplemented.

The investigators began by collecting blood from cattle, pigs, and chickens under protocols approved by the Animal Experiment Ethics Committee of Chung-Ang University, with approvals numbered 202401030030 and 202301020084. All animal procedures were conducted in accordance with relevant institutional and national guidelines. Because livestock serum would be derived from animals already processed for food, the approach sidesteps the most persistent ethical objection to FBS, namely its fetal origin, while also promising a supply chain that is more abundant, more traceable, and potentially far cheaper than the fetal serum market.

The first stage of the work involved comprehensive biochemical and physicochemical profiling of the sera. The researchers measured parameters that matter deeply to cell biologists: osmolality, pH, protein content, and the biochemical composition that determines whether a serum can sustain living cells. All of the livestock sera tested met sterility requirements, a crucial threshold for any candidate medium component destined for food production. Notably, however, some of the livestock sera showed deviations in physicochemical parameters relative to FBS, deviations that would later inform the optimization strategy. This finding matters because serum is not a simple solution but a complex biological cocktail of growth factors, hormones, attachment factors, carrier proteins, and lipids, and even modest differences in composition can ripple through cell behavior in culture.

With the sera characterized, the team turned to the functional heart of the study: proliferation and differentiation assays using bovine satellite cells, the muscle stem cells responsible for postnatal muscle growth and regeneration. These cells are the workhorses of cultured meat, because they are the ones that must divide vigorously to build biomass and then differentiate and fuse into the multinucleated muscle fibers that give meat its texture and protein content. The results were strikingly species-dependent. Bovine and porcine sera consistently supported robust proliferation, myogenic differentiation, and long-term expansion of the satellite cells. Chicken serum, by contrast, failed to deliver the same performance, unable to sustain the growth trajectory that bovine and porcine sera achieved. For a field that has mostly treated serum as interchangeable, this species-specific divergence is a meaningful data point, suggesting that donor species compatibility should be a central design criterion in serum substitution.

Perhaps the most demanding test was long-term serial passaging. In industrial cultured meat bioprocessing, cells cannot simply be grown once and harvested; they must be expanded repeatedly, through many rounds of passaging, to generate the enormous cell numbers required to fill bioreactors at commercial scale. Serum that supports a few days of growth is of limited value if the cells senesce or lose their myogenic potential after several passages. The optimized bovine- and porcine-based substitutes supported stable proliferation during serial passaging, indicating that the cells retained their proliferative capacity and functional identity over extended culture. This stability is precisely the property that distinguishes a laboratory curiosity from a scalable industrial input.

The optimization itself represents the technical centerpiece of the work. Raw livestock serum, while competent, did not fully match FBS in every respect, so the researchers enhanced the final formulations with targeted supplements. Two additives proved particularly effective: lipid-rich albumin and insulin-transferrin-selenium, the latter supplied at a concentration of 25 micrograms per milliliter. The logic of these supplements is grounded in cell physiology. Albumin serves as a carrier protein for fatty acids and other lipids, which muscle cells require in substantial quantities for membrane synthesis and energy metabolism but which adult serum can deliver inconsistently. Insulin provides anabolic signaling that drives glucose and amino acid uptake, transferrin supplies iron in a controlled and bioavailable form, and selenium acts as an antioxidant cofactor that protects cells from oxidative stress during rapid proliferation. Together, these supplements significantly enhanced cellular performance, closing the gap between livestock serum and FBS to the point of full functional replacement.

The economic implications may prove as consequential as the biological ones. Fetal bovine serum is one of the most expensive components of cell culture medium, with prices driven by limited supply, batch-to-batch variability, and demand from pharmaceutical and research markets that far exceed anything the cultured meat industry can command. Cost analysis conducted by the Chung-Ang University team revealed that replacing FBS with the optimized livestock-derived serum formulations reduced total medium cost by 62.6 percent. Given that medium costs are widely regarded as the single largest barrier to price parity between cultured meat and conventional meat, a reduction of this magnitude in a core medium ingredient represents a substantial step toward commercial viability. The fact that the raw material, adult livestock serum, is an abundant byproduct of existing slaughter operations adds a circular economy dimension, transforming a low-value waste stream into a high-value input.

The study does not claim that every obstacle has been cleared. The researchers note that while all sera met sterility requirements, the deviations in physicochemical parameters among some livestock sera underscore the need for standardization, since cultured meat production at scale will demand consistent, reproducible serum quality from batch to batch. The poor performance of chicken serum also illustrates that a single universal substitute may not exist, and that serum selection may need to be matched to cell line and process. Regulatory pathways for food-grade serum of slaughter origin will likewise require attention as the technology moves toward commercial deployment. Nevertheless, the demonstration that bovine and porcine sera can fully replace FBS, sustain serial passaging, and do so at dramatically reduced cost addresses the three most cited weaknesses of FBS at once: ethics, scalability, and price.

Funded through the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry via the High Value-added Food Technology Development Program under the Ministry of Agriculture, Food and Rural Affairs, the work reflects a growing national commitment to cell-based food technology. For an industry that has struggled to reconcile its sustainability narrative with its dependence on fetal calf blood, optimized slaughter livestock serum offers a resolution that is effective, scalable, and ethically aligned. If subsequent scale-up studies confirm these results in suspension culture and bioreactor settings, the humble byproduct of the slaughterhouse floor may become one of the key ingredients that finally allows cultured meat to grow up.

Subject of Research: Optimization of slaughter livestock serum as a fetal bovine serum substitute for bovine satellite cell culture in cultured meat production

Article Title: Optimization of slaughter livestock serum as an alternative to fetal bovine serum in cultured meat application

Article References: Lee, D.-Y., Mariano, E., Park, J. W., Namkung, S., Choi, S. Y., Lee, W. J., Shin, Y. W., Bok, C. H., & Hur, S. J. (2026). Optimization of slaughter livestock serum as an alternative to fetal bovine serum in cultured meat application. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14017-3

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14017-3

Keywords: cultured meat, fetal bovine serum, livestock serum, cell culture, bovine satellite cells, myogenic differentiation, serum substitutes, bioprocessing, cell proliferation, medium cost reduction, food biotechnology, sustainable food production